Why FDA 510(k) Clearance Is Excluded from the Reliance Pathway

1. Key takeaways

Among the five Scope Exclusions of MDS-G030 (V1.0 / 2026-09-09), item 2 covers products granted access mainly by demonstrating substantial equivalence to a predicate device already on the market; the reliance pathway does not apply to them. This directly excludes clearances granted under the US FDA’s 510(k). What must be kept clear is that the exclusion targets the pathway, not the country: the FDA remains within the list of 6 RRAs, and FDA channels that involve substantive review are outside the reach of this item. Chinese manufacturers have three viable responses: switch to an existing approval the SFDA can rely on (such as CE under the EU MDR, TGA’s ARTG inclusion, or Health Canada’s MDL); add a PMDA or MHRA approval; or return to the conventional MDMA route with the complete technical file under MDS-REQ1, in which case the review time is no longer the 35–60 working-day reliance band. Regulatory information verified as of 29 October 2026.

• Scope Exclusions item 2 removes products cleared mainly by predicate substantial equivalence — including FDA 510(k) clearances.
• The exclusion targets the pathway, not the country: the FDA stays on the 6-RRA list.
• Three responses: swap to another RRA approval, add a PMDA/MHRA approval, or run the conventional MDMA with a complete technical file.
• Outside the reliance band, the review clock follows the conventional MDMA rhythm.

2. Legal basis

The following instruments define the exclusion, its position within the RRA framework, and the fallback technical file structure for products that cannot use reliance.

3. Expert insights

1. The exclusion targets the pathway, not the country

The wording deserves a literal reading: what is excluded are products granted access mainly by demonstrating substantial equivalence to a marketed comparator device. The subject is the manner in which access was obtained, not the authority that issued the approval. In practice this is often misread as United States approvals not being recognised in Saudi Arabia, which deters FDA holders altogether. The actual boundary is that the SFDA declines to rely on the argument method — an access process that performed no independent conformity assessment of the product itself — rather than on the stamp. Within the same company, a product line cleared through FDA PMA or De Novo and a line holding only a 510(k) are not in the same position under MDS-G030. GRZAN recommends seeking written confirmation from the SFDA on this question before filing, keeping the reply on record, and only then fixing the Saudi filing strategy.

2. Trust can only be placed in conclusions already independently assessed

To put it bluntly: the entire legitimacy of reliance lies in the SFDA borrowing a conclusion that a third-party regulator reached after independently assessing this one product. Borrowing presupposes that the conclusion exists. The 510(k) mechanism works by the manufacturer selecting a predicate device, arguing that its product is substantially equivalent, and submitting that argument to the FDA; the FDA’s conclusion is that the argument holds — not that the agency performed a complete safety and performance assessment of the product. The independently evaluated object is the logic chain of the argument, not the device itself, whose conclusions on safety and effectiveness are largely extended from the predicate. If the SFDA relied on a 510(k), it would be relying on a family of predicate devices it has never assessed, shifting regulatory responsibility to a third party outside its own chain of control. The same logic drives Scope Exclusions item 1, the self-registration or self-declaration pathway: access without a conformity assessment body produces no conclusion worth relying on. Under the EU MDR, the self-declaration route for some Class I devices falls on the same clause.

3. Sequencing the three exits depends on the company’s global timing

The first exit is to swap the card: if the same device already holds CE under the EU MDR (assessed by a notified body), TGA ARTG inclusion, a Health Canada MDL, or PMDA or MHRA approval, switch the reference authority to that one — provided the version filed in Saudi Arabia remains technically identical to the version approved there. This carries the lowest marginal cost. The second exit is to add a certificate: build on the existing 510(k) by first obtaining a higher-intensity approval (for example De Novo or PMA) and then returning to the reliance route — the time cost is high, but for product lines already entrenched in the US market it is a natural extension. The third exit is to accept that no shortcut applies and file a conventional MDMA with the complete technical file per MDS-REQ1 Annex (3) or Annex (4), re-planning budget and cycle. The pathway overview and time account are in https://www.grzan.cn/regulations/saudi/sfda-reliance-pathway-mds-g030-12 ; on whether ISO 13485 or MDSAP certificates should be secured first, see https://www.grzan.cn/regulations/saudi/mdsap-certificate-as-qms-evidence-15 .

4. Practical recommendations

• Trace the access method for every product line first: determine whether the reference approval rests on substantial equivalence, self-declaration, or assessment by a third-party conformity assessment body.
• For products holding a 510(k), do not give up on the assumption that the road is closed; check first whether the same product has CE, TGA or Health Canada approvals that can be substituted.
• If only a 510(k) exists, re-point the rationale to the conventional MDMA: re-plan the document list and owners on the basis of the complete Annex (3) / Annex (4).
• Companies phasing their overseas registrations should write securing a non-510(k) approval into the two-year global registration roadmap, not bolt it on afterwards.
• For product lines heading toward PMA or De Novo, prepare a written applicability argument before filing in Saudi Arabia and, where necessary, ask the SFDA and keep the reply.
• Note that if the FDA approval itself is recalled, suspended or restricted during its validity, exclusion item 4 of MDS-G030 is triggered as well.
• Do not apply the 35–60 working-day band to the time budget; re-plan to the conventional MDMA review rhythm and include the time for SFDA deficiency requests.

5. Verification checklist

• □ The access method behind every RRA approval to be relied on has been identified
• □ Models holding only a 510(k) have been removed from the reliance application list, or replaced with reference approvals obtained other than by substantial equivalence
• □ Reference approvals have been checked as valid and not recalled, suspended, withdrawn or restricted by the RRA
• □ Products entering Saudi Arabia on a 510(k) only have had their technical file list re-planned per Annex (3) or Annex (4)
• □ The time budget now follows the conventional MDMA account, not the 35–60 working-day band
• □ For PMA / De Novo product lines, a written applicability argument for the SFDA is prepared and replies recorded
• □ The ledger notes that the FDA remains one of the 6 RRAs, to avoid later misjudgements that United States approvals are uniformly void

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team manages SFDA MDMA applications across classes, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzan.com